Akari Reports $19.3M Loss, Extends Cash Runway to December, Announces Whitehawk Collaboration
AKTX has more than doubled off its 52-week low of $3.015.
Summary
Akari Therapeutics reported a $19.3M H1 2026 net loss, extended cash runway to December 2026, and disclosed a new Whitehawk collaboration and a huge authorized share increase.
Key Events · Earnings and Guidance · AKTX
-
Net Loss Widens to $19.3M
Six-month net loss of $19.3 million, up from $5.6 million in H1 2025, driven by $12.1 million in non-cash impairment charges on goodwill and IPR&D.
-
Cash Runway Only to December 2026
Cash balance of $7.7 million as of June 30, 2026, funds operations only into December 2026; going concern warning reiterated.
-
Authorized Shares Soar to 4.37 Trillion
Shareholders approved an increase in authorized ordinary shares to 4,365,687,180,943, enabling massive future dilution.
-
Whitehawk Collaboration Announced
Subsequent event: strategic research collaboration with Whitehawk Therapeutics to evaluate PH1 payload technology in combination with Whitehawk's ADC platform.
Analysis · AKTX · Life Sciences
Akari Therapeutics' Q2 2026 10-Q reveals a $19.3 million net loss for the first half of 2026, driven by $12.1 million in non-cash impairment charges on goodwill and IPR&D. Cash of $7.7 million at June 30, 2026, extends the runway only to December 2026, and the company reiterates substantial doubt about its ability to continue as a going concern. The filing also discloses a strategic research collaboration with Whitehawk Therapeutics and a massive increase in authorized shares to over 4.3 trillion, setting the stage for further extreme dilution.
At the time of this filing, AKTX was trading at $7.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.2M. The 52-week trading range was $3.02 to $49.60. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.